Tags

Type your tag names separated by a space and hit enter

Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.
Aliment Pharmacol Ther 2014; 40(1):51-62AP

Abstract

BACKGROUND

The importance of interactions between the host and gut microbiota in the pathogenesis of irritable bowel syndrome (IBS) is becoming increasingly apparent. Probiotics offer a potential new treatment for IBS, but current results are conflicting, largely as a result of poorly designed trials and nonstandardisation of outcome measures.

AIM

To assess the efficacy of a liquid, multi-strain probiotic (Symprove) in IBS.

METHODS

A single-centre, randomised, double-blind, placebo-controlled trial of adult patients with symptomatic IBS. Patients received 12 weeks of treatment with the probiotic or placebo (1 mL/kg/day). The primary efficacy measure was the difference in change in the IBS symptom severity score (IBS-SSS) between probiotic vs. placebo at week 12. Secondary outcome measures included change in the IBS quality of life (IBS-QOL) score and change in the IBS-SSS symptom component scores.

RESULTS

A total of 186 patients were randomised and 152 patients completed the study. The mean change in IBS-SSS was -63.3 probiotic vs. -28.3 placebo. The mean difference in the IBS-SSS was statistically significant [-35.0 (95% CI; -62.03, -7.87); P = 0.01]. There was no significant improvement in the IBS-QOL. No serious adverse events were reported.

CONCLUSIONS

The multi-strain probiotic was associated with a statistically significant improvement in overall symptom severity in patients with IBS, and was well tolerated. These results suggest this probiotic confers benefit in IBS and deserves further investigation (ISRCTN identifier: 77512412).

Authors+Show Affiliations

Darent Valley Hospital, Dartford, Kent, UK.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24815298

Citation

Sisson, G, et al. "Randomised Clinical Trial: a Liquid Multi-strain Probiotic Vs. Placebo in the Irritable Bowel Syndrome--a 12 Week Double-blind Study." Alimentary Pharmacology & Therapeutics, vol. 40, no. 1, 2014, pp. 51-62.
Sisson G, Ayis S, Sherwood RA, et al. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study. Aliment Pharmacol Ther. 2014;40(1):51-62.
Sisson, G., Ayis, S., Sherwood, R. A., & Bjarnason, I. (2014). Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study. Alimentary Pharmacology & Therapeutics, 40(1), pp. 51-62. doi:10.1111/apt.12787.
Sisson G, et al. Randomised Clinical Trial: a Liquid Multi-strain Probiotic Vs. Placebo in the Irritable Bowel Syndrome--a 12 Week Double-blind Study. Aliment Pharmacol Ther. 2014;40(1):51-62. PubMed PMID: 24815298.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study. AU - Sisson,G, AU - Ayis,S, AU - Sherwood,R A, AU - Bjarnason,I, Y1 - 2014/05/11/ PY - 2013/11/29/received PY - 2013/12/15/revised PY - 2014/04/16/revised PY - 2014/04/17/accepted PY - 2014/5/13/entrez PY - 2014/5/13/pubmed PY - 2014/9/19/medline SP - 51 EP - 62 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 40 IS - 1 N2 - BACKGROUND: The importance of interactions between the host and gut microbiota in the pathogenesis of irritable bowel syndrome (IBS) is becoming increasingly apparent. Probiotics offer a potential new treatment for IBS, but current results are conflicting, largely as a result of poorly designed trials and nonstandardisation of outcome measures. AIM: To assess the efficacy of a liquid, multi-strain probiotic (Symprove) in IBS. METHODS: A single-centre, randomised, double-blind, placebo-controlled trial of adult patients with symptomatic IBS. Patients received 12 weeks of treatment with the probiotic or placebo (1 mL/kg/day). The primary efficacy measure was the difference in change in the IBS symptom severity score (IBS-SSS) between probiotic vs. placebo at week 12. Secondary outcome measures included change in the IBS quality of life (IBS-QOL) score and change in the IBS-SSS symptom component scores. RESULTS: A total of 186 patients were randomised and 152 patients completed the study. The mean change in IBS-SSS was -63.3 probiotic vs. -28.3 placebo. The mean difference in the IBS-SSS was statistically significant [-35.0 (95% CI; -62.03, -7.87); P = 0.01]. There was no significant improvement in the IBS-QOL. No serious adverse events were reported. CONCLUSIONS: The multi-strain probiotic was associated with a statistically significant improvement in overall symptom severity in patients with IBS, and was well tolerated. These results suggest this probiotic confers benefit in IBS and deserves further investigation (ISRCTN identifier: 77512412). SN - 1365-2036 UR - https://www.unboundmedicine.com/medline/citation/24815298/Randomised_clinical_trial:_A_liquid_multi_strain_probiotic_vs__placebo_in_the_irritable_bowel_syndrome__a_12_week_double_blind_study_ L2 - https://doi.org/10.1111/apt.12787 DB - PRIME DP - Unbound Medicine ER -